Equillium Inc at Stifel Healthcare Conference Transcript
We'll get started with the next session. Thank you, everyone, for coming. My name is Dae Gon Ha. I'm one of the biotech analysts here. Next session is with Equillium. And from Equillium, we have VP, IR, and Corporate Communications, Michael Moore. And Michael is going to be walking us through the presentation. So with that, Michael, thank you.
Thanks, Dae Gon. Thanks, Stifel, for us having here. Thanks, everybody, in the room and on the webcast. Thanks for here -- for an update on Equillium.
So Equillium is a development-stage biotechnology company. Before I get into that, just take a look at the forward-looking statements, of course. A development-stage biotechnology company with three clinical assets, all first in class. Our foundational asset, the itolizumab, is an anti-CD6. And we recently announced earlier this year the acquisition of Bioniz, bringing in a development-drug platform as well as two multi-cytokine
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
